Aquilo Capital Management
Latest statistics and disclosures from Aquilo Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are XBI, MRUS, Loxo Oncology, FATE, Aduro Biotech, and represent 75.84% of Aquilo Capital Management's stock portfolio.
- Added to shares of these 8 stocks: XBI (+$48M), Synlogic (+$9.8M), XENE (+$7.8M), FATE (+$6.6M), SPRO, MRUS, Aduro Biotech, CTMX.
- Started 1 new stock position in XENE.
- Reduced shares in these 6 stocks: AUTL, GLPG, CLLS, Loxo Oncology, Five Prime Therapeutics, MOR.
- Sold out of its positions in AUTL, CLLS, Five Prime Therapeutics.
- Aquilo Capital Management was a net buyer of stock by $63M.
- Aquilo Capital Management has $239M in assets under management (AUM), dropping by 96.46%.
- Central Index Key (CIK): 0001750122
Portfolio Holdings for Aquilo Capital Management
Aquilo Capital Management holds 12 positions in its portfolio as reported in the September 2018 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| SPDR S&P Biotech (XBI) | 44.1 | $106M | +83% | 1.1M | 95.87 |
|
| Merus N V (MRUS) | 10.7 | $26M | +3% | 1.3M | 19.74 |
|
| Loxo Oncology | 7.8 | $19M | -13% | 109k | 170.83 |
|
| Fate Therapeutics (FATE) | 6.7 | $16M | +69% | 985k | 16.29 |
|
| Aduro Biotech | 6.5 | $16M | +4% | 2.1M | 7.35 |
|
| Synlogic | 5.9 | $14M | +225% | 998k | 14.21 |
|
| Cytomx Therapeutics (CTMX) | 5.2 | $13M | +3% | 675k | 18.50 |
|
| Pieris Pharmaceuticals | 4.6 | $11M | 2.0M | 5.60 |
|
|
| Spero Therapeutics (SPRO) | 3.5 | $8.4M | +91% | 800k | 10.51 |
|
| Xenon Pharmaceuticals (XENE) | 3.3 | $7.8M | NEW | 593k | 13.20 |
|
| Galapagos Nv- (GLPG) | 1.5 | $3.5M | -52% | 31k | 112.42 |
|
| Morphosys (MOR) | 0.1 | $243k | -9% | 9.1k | 26.74 |
|
Past Filings by Aquilo Capital Management
SEC 13F filings are viewable for Aquilo Capital Management going back to 2018
- Aquilo Capital Management 2018 Q3 filed Nov. 14, 2018
- Aquilo Capital Management 2018 Q2 filed Aug. 14, 2018